Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Ovarian Cancer | Research

FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma

Authors: Tong Lou, Chongdong Liu, Hong Qu, Zhiqiang Zhang, Shuzhen Wang, Huiyu Zhuang

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

FOXA1 is associated with malignant tumors, but the function of FOXA1 in EOC is unclear. HDAC3 can influence the proliferation, migration and invasion ability of EOC. In this study, we wanted to explore the function of FOXA1 in ovarian cancer and the relationship between HDAC3 and FOXA1.The expression of HDAC3 and FOXA1 was detected by immunohistochemical staining of primary lesions from 127 epithelial ovarian carcinoma patients. A proliferation assay, a Transwell assay, an apoptosis assay and animal experiments were used to assess the proliferation, invasion and apoptosis abilities of ovarian cancer cells before and after transfection with FOXA1. The relevance of the in vitro findings was confirmed in xenografts. The H-scores for FOXA1 and HDAC3 staining in FIGO stage III-IV were noticeably higher and predicted adverse clinical outcomes in patients with ovarian cancer. The expression level of HDAC3 was significantly correlated with the expression level of FOXA1. Invasion, proliferation and apoptosis capacity and tumor formation were decreased in the FOXA1-knockdown cells. Experiments in xenografts confirmed that HDAC3 mediated tumor formation. In conclusion, FOXA1 can be modulated by HDAC3 through the Wnt/β-catenin signaling pathway, and FOXA1 plays essential roles in the proliferation, apoptosis and invasion of EOC cell lines and xenograft experiments.
Literature
1.
go back to reference Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
go back to reference Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.CrossRef Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.CrossRef
3.
go back to reference Armstrong D. Update on treatment options for newly diagnosed ovarian cancer. Clin Adv Hematol Oncol. 2010;8(10):675–8.PubMed Armstrong D. Update on treatment options for newly diagnosed ovarian cancer. Clin Adv Hematol Oncol. 2010;8(10):675–8.PubMed
4.
go back to reference Kang KW, et al. Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma. Oncol Rep. 2014;32(1):189–98.CrossRef Kang KW, et al. Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma. Oncol Rep. 2014;32(1):189–98.CrossRef
5.
go back to reference Xu G, Zhu H, Zhang M, Xu J. Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5. Int J Mol Med. 2018;41(1):155–63.PubMed Xu G, Zhu H, Zhang M, Xu J. Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5. Int J Mol Med. 2018;41(1):155–63.PubMed
6.
go back to reference Wilson AJ, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281(19):13548–58.CrossRef Wilson AJ, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281(19):13548–58.CrossRef
7.
go back to reference Jiao F, et al. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. Int J Oncol. 2014;45(4):1523–30.CrossRef Jiao F, et al. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. Int J Oncol. 2014;45(4):1523–30.CrossRef
8.
go back to reference Kim H, Kim Y, Goh H, Jeoung D. Histone deacetylase-3/CAGE axis targets EGFR signaling and regulates the response to anti-cancer drugs. Mol Cells. 2016;39(3):229–41.CrossRef Kim H, Kim Y, Goh H, Jeoung D. Histone deacetylase-3/CAGE axis targets EGFR signaling and regulates the response to anti-cancer drugs. Mol Cells. 2016;39(3):229–41.CrossRef
9.
go back to reference Guan J, et al. Overexpression of caveolin-1 reduces Taxol resistance in human osteosarcoma cells by attenuating PI3K-Akt-JNK dependent autophagy. Exp Ther Med. 2016;12(5):2815–22.CrossRef Guan J, et al. Overexpression of caveolin-1 reduces Taxol resistance in human osteosarcoma cells by attenuating PI3K-Akt-JNK dependent autophagy. Exp Ther Med. 2016;12(5):2815–22.CrossRef
10.
go back to reference Lou T, Zhuang H, Liu C, Zhang Z. HDAC3 positively regulates HE4 expression to promote ovarian carcinoma progression. Arch Biochem Biophys. 2019;675:108044.CrossRef Lou T, Zhuang H, Liu C, Zhang Z. HDAC3 positively regulates HE4 expression to promote ovarian carcinoma progression. Arch Biochem Biophys. 2019;675:108044.CrossRef
11.
go back to reference Serandour AA, et al. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 2011;21(4):555–65.CrossRef Serandour AA, et al. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 2011;21(4):555–65.CrossRef
12.
go back to reference Wang D, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474(7351):390–4.CrossRef Wang D, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474(7351):390–4.CrossRef
13.
go back to reference Yang YA, Yu J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2015;2(2):144–51.CrossRef Yang YA, Yu J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2015;2(2):144–51.CrossRef
14.
go back to reference Gm B, Ra K. FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep. 2012;32(2):113–30.CrossRef Gm B, Ra K. FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep. 2012;32(2):113–30.CrossRef
15.
go back to reference Gao D, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176–87.CrossRef Gao D, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176–87.CrossRef
16.
go back to reference Hj J, et al. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun. 2014;5:3972.CrossRef Hj J, et al. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun. 2014;5:3972.CrossRef
17.
go back to reference Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.CrossRef Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.CrossRef
18.
go back to reference Gough NR. Focus issue: Wnt and β-catenin signaling in development and disease. Sci Signal. 2012;5(206):eg2.CrossRef Gough NR. Focus issue: Wnt and β-catenin signaling in development and disease. Sci Signal. 2012;5(206):eg2.CrossRef
19.
go back to reference Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev. 2008;22(17):2308–41.CrossRef Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev. 2008;22(17):2308–41.CrossRef
20.
go back to reference Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013;131(3):772–9.CrossRef Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013;131(3):772–9.CrossRef
21.
go back to reference Lu Q, et al. CK19 promotes ovarian cancer development by impacting on Wnt/β-catenin pathway. Onco Targets Ther. 2020;13:2421–31.CrossRef Lu Q, et al. CK19 promotes ovarian cancer development by impacting on Wnt/β-catenin pathway. Onco Targets Ther. 2020;13:2421–31.CrossRef
22.
go back to reference Wang X, et al. Expression of histone deacetylase 3 instructs alveolar type I cell differentiation by regulating a Wnt signaling niche in the lung. Dev Biol. 2016;414(2):161–9.CrossRef Wang X, et al. Expression of histone deacetylase 3 instructs alveolar type I cell differentiation by regulating a Wnt signaling niche in the lung. Dev Biol. 2016;414(2):161–9.CrossRef
23.
go back to reference Prat J. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87–9.CrossRef Prat J. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87–9.CrossRef
24.
go back to reference Ha A, et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 2015;17:24.CrossRef Ha A, et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 2015;17:24.CrossRef
25.
go back to reference Lou T, Liu C, Zhang Z. N-myc downstream-regulated gene 1 and endometriosis: a minireview. Crit Rev Eukaryot Gene Expr. 2017;27(4):341–5.CrossRef Lou T, Liu C, Zhang Z. N-myc downstream-regulated gene 1 and endometriosis: a minireview. Crit Rev Eukaryot Gene Expr. 2017;27(4):341–5.CrossRef
26.
go back to reference Lee CK, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol. 2013;24(4):937–43.CrossRef Lee CK, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol. 2013;24(4):937–43.CrossRef
27.
go back to reference Yin M, et al. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011;104(1):29–36.CrossRef Yin M, et al. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011;104(1):29–36.CrossRef
28.
go back to reference Abdel Ghafar MT, Gharib F, Al-Ashmawy GM, Mariah RA. Serum high-temperature-required protein A2: a potential biomarker for the diagnosis of breast cancer. Gene Rep. 2020;20:100706.CrossRef Abdel Ghafar MT, Gharib F, Al-Ashmawy GM, Mariah RA. Serum high-temperature-required protein A2: a potential biomarker for the diagnosis of breast cancer. Gene Rep. 2020;20:100706.CrossRef
30.
go back to reference Abdel Ghafar MT, et al. Utility of serum neuropilin-1 and angiopoietin-2 as markers of hepatocellular carcinoma. J Investig Med. 2021;69(6):1222–9.CrossRef Abdel Ghafar MT, et al. Utility of serum neuropilin-1 and angiopoietin-2 as markers of hepatocellular carcinoma. J Investig Med. 2021;69(6):1222–9.CrossRef
31.
go back to reference Kaestner K, Knochel W, Martinez D. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 2000;14(2):142–6.CrossRef Kaestner K, Knochel W, Martinez D. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 2000;14(2):142–6.CrossRef
32.
go back to reference Wang K, et al. Clinical significance and prognostic value of Forkhead box A1 expression in human epithelial ovarian cancer. Oncol Lett. 2018;15(4):4457–62.PubMedPubMedCentral Wang K, et al. Clinical significance and prognostic value of Forkhead box A1 expression in human epithelial ovarian cancer. Oncol Lett. 2018;15(4):4457–62.PubMedPubMedCentral
33.
go back to reference Carroll JS, Brown M. Estrogen receptor target gene: an evolving concept. Mol Endocrinol. 2006;20(8):1707–14.CrossRef Carroll JS, Brown M. Estrogen receptor target gene: an evolving concept. Mol Endocrinol. 2006;20(8):1707–14.CrossRef
34.
go back to reference Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012;148(1–2):72–83.CrossRef Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012;148(1–2):72–83.CrossRef
35.
go back to reference Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 2010;70(5):2115–25.CrossRef Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 2010;70(5):2115–25.CrossRef
36.
go back to reference Yuan Z, Ye M, Qie J, Ye T. FOXA1 promotes cell proliferation and suppresses apoptosis in HCC by directly regulating miR-212-3p/FOXA1/AGR2 signaling pathway. Onco Targets Ther. 2020;13:5231–40.CrossRef Yuan Z, Ye M, Qie J, Ye T. FOXA1 promotes cell proliferation and suppresses apoptosis in HCC by directly regulating miR-212-3p/FOXA1/AGR2 signaling pathway. Onco Targets Ther. 2020;13:5231–40.CrossRef
37.
go back to reference Liu B, et al. FOXA1 promotes proliferation, migration and invasion by transcriptional activating KRT7 in human gastric cancer cells. J Biol Regul Homeost Agents. 2019;33(4):1041–50.PubMed Liu B, et al. FOXA1 promotes proliferation, migration and invasion by transcriptional activating KRT7 in human gastric cancer cells. J Biol Regul Homeost Agents. 2019;33(4):1041–50.PubMed
38.
go back to reference Godman CA, et al. HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther. 2008;7(10):1570–80.CrossRef Godman CA, et al. HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther. 2008;7(10):1570–80.CrossRef
Metadata
Title
FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma
Authors
Tong Lou
Chongdong Liu
Hong Qu
Zhiqiang Zhang
Shuzhen Wang
Huiyu Zhuang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-03224-3

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine